153 related articles for article (PubMed ID: 11727307)
1. Thrombin receptor antagonists as novel therapeutic targets.
Chackalamannil S
Curr Opin Drug Discov Devel; 2001 Jul; 4(4):417-27. PubMed ID: 11727307
[TBL] [Abstract][Full Text] [Related]
2. G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents.
Chackalamannil S
Curr Top Med Chem; 2003; 3(10):1115-23. PubMed ID: 12769712
[TBL] [Abstract][Full Text] [Related]
3. Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents.
Chackalamannil S; Xia Y
Expert Opin Ther Pat; 2006 Apr; 16(4):493-505. PubMed ID: 20144050
[TBL] [Abstract][Full Text] [Related]
4. Thrombin receptors and their antagonists: an update on the patent literature.
Cirino G; Severino B
Expert Opin Ther Pat; 2010 Jul; 20(7):875-84. PubMed ID: 20450349
[TBL] [Abstract][Full Text] [Related]
5. Thrombin and protease-activated receptors (PARs) in atherothrombosis.
Martorell L; Martínez-González J; Rodríguez C; Gentile M; Calvayrac O; Badimon L
Thromb Haemost; 2008 Feb; 99(2):305-15. PubMed ID: 18278179
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1997 Jul; 78(1):736-41. PubMed ID: 9198248
[TBL] [Abstract][Full Text] [Related]
7. Thrombin receptor antagonists.
Seiler SM
Semin Thromb Hemost; 1996; 22(3):223-32. PubMed ID: 8836006
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of protease-activated receptor-1 antagonists.
Derian CK; Maryanoff BE; Zhang HC; Andrade-Gordon P
Expert Opin Investig Drugs; 2003 Feb; 12(2):209-21. PubMed ID: 12556215
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
10. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.
Andrade-Gordon P; Derian CK; Maryanoff BE; Zhang HC; Addo MF; Cheung Wm ; Damiano BP; D'Andrea MR; Darrow AL; de Garavilla L; Eckardt AJ; Giardino EC; Haertlein BJ; McComsey DF
J Pharmacol Exp Ther; 2001 Jul; 298(1):34-42. PubMed ID: 11408522
[TBL] [Abstract][Full Text] [Related]
11. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases.
Ahn HS; Chackalamannil S; Boykow G; Graziano MP; Foster C
Curr Pharm Des; 2003; 9(28):2349-65. PubMed ID: 14529396
[TBL] [Abstract][Full Text] [Related]
12. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice.
Major CD; Santulli RJ; Derian CK; Andrade-Gordon P
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):931-9. PubMed ID: 12676802
[TBL] [Abstract][Full Text] [Related]
13. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
Kaufmann R; Rahn S; Pollrich K; Hertel J; Dittmar Y; Hommann M; Henklein P; Biskup C; Westermann M; Hollenberg MD; Settmacher U
J Cell Physiol; 2007 Jun; 211(3):699-707. PubMed ID: 17323377
[TBL] [Abstract][Full Text] [Related]
15. G-protein-coupled receptors as signaling targets for antiplatelet therapy.
Smyth SS; Woulfe DS; Weitz JI; Gachet C; Conley PB; Goodman SG; Roe MT; Kuliopulos A; Moliterno DJ; French PA; Steinhubl SR; Becker RC;
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):449-57. PubMed ID: 19023091
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.
Derian CK; Damiano BP; Addo MF; Darrow AL; D'Andrea MR; Nedelman M; Zhang HC; Maryanoff BE; Andrade-Gordon P
J Pharmacol Exp Ther; 2003 Feb; 304(2):855-61. PubMed ID: 12538843
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.
Tsopanoglou NE; Maragoudakis ME
Semin Thromb Hemost; 2007 Oct; 33(7):680-7. PubMed ID: 18000795
[TBL] [Abstract][Full Text] [Related]
18. Differential activation and inhibition of human platelet thrombin receptors by structurally distinct alpha-, beta- and gamma-thrombin.
Soslau G; Goldenberg SJ; Class R; Jameson B
Platelets; 2004 May; 15(3):155-66. PubMed ID: 15203717
[TBL] [Abstract][Full Text] [Related]
19. Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans.
Gudmundsdóttir IJ; Lang NN; Boon NA; Ludlam CA; Webb DJ; Fox KA; Newby DE
J Am Coll Cardiol; 2008 May; 51(18):1749-56. PubMed ID: 18452780
[TBL] [Abstract][Full Text] [Related]
20. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation.
Fiorucci S; Antonelli E; Distrutti E; Severino B; Fiorentina R; Baldoni M; Caliendo G; Santagada V; Morelli A; Cirino G
Hepatology; 2004 Feb; 39(2):365-75. PubMed ID: 14767989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
